

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT2954732

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CHARLESTON LABORATORIES, INC.	07/24/2014
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	LOCL PHARMA, INC.
<b>Street Address:</b>	EIGHT WEST LAUREL STREET
<b>Internal Address:</b>	1ST FLOOR
<b>City:</b>	GEORGETOWN
<b>State/Country:</b>	DELAWARE
<b>Postal Code:</b>	19947-1424
<b>PROPERTY NUMBERS Total: 22</b>	
<b>Property Type</b>	<b>Number</b>
<b>PCT Number:</b>	US2007080831
<b>Application Number:</b>	60948375
<b>Application Number:</b>	60850451
<b>Application Number:</b>	60921563
<b>Application Number:</b>	14099432
<b>Application Number:</b>	13347552
<b>Application Number:</b>	14036946
<b>Application Number:</b>	61321199
<b>PCT Number:</b>	US2010041433
<b>Application Number:</b>	61223999
<b>Application Number:</b>	61224424
<b>Application Number:</b>	14244455
<b>Application Number:</b>	61750976
<b>Application Number:</b>	61926777
<b>Application Number:</b>	61916539
<b>Application Number:</b>	61915723
<b>Application Number:</b>	61977845
<b>Application Number:</b>	62020597
<b>Application Number:</b>	61926779
<b>Patent Number:</b>	8653066

PATENT

Property Type	Number
Patent Number:	8124126
Patent Number:	8728522

**CORRESPONDENCE DATA**

**Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Email:** patentdocket@wsgr.com

**Correspondent Name:** WILSON SONSINI GOODRICH & ROSATI

**Address Line 1:** 650 PAGE MILL ROAD

**Address Line 4:** PALO ALTO, CALIFORNIA 94304-1050

**ATTORNEY DOCKET NUMBER:** 35681-700

**NAME OF SUBMITTER:** LOUIS D. LIETO

**SIGNATURE:** /Louis D. Lieto/

**DATE SIGNED:** 07/25/2014

**Total Attachments: 3**

source=CharlestonLaboratoriesIncLOCLPharmaIncCorporatePatentAssignment#page1.tif

source=CharlestonLaboratoriesIncLOCLPharmaIncCorporatePatentAssignment#page2.tif

source=CharlestonLaboratoriesIncLOCLPharmaIncCorporatePatentAssignment#page3.tif

WHEREAS, Charleston Laboratories, Inc. (hereinafter "Assignor"), owns the entire right, title and interest in and to the inventions disclosed in the Application(s), and in and to all embodiments of the inventions, heretofore conceived, made or discovered (collectively hereinafter referred to as "Inventions") as set forth in Annex A hereto:

WHEREAS, LOCL Pharma, Inc., a corporation of the State of Delaware, having a place of business at Eight West Laurel Street, 1<sup>st</sup> Floor, Georgetown, DE 19947-1424, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; and (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing.

2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by the Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by the parties (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives.

4. Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Assignor hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

CORPORATE TO CORPORATE ASSIGNMENT

Docket Number 35681-700

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the dates written below:

ASSIGNOR Charleston Laboratories, Inc.


Date: 7/24/2014 Ryan Baker, Chief Operating Officer

State/Commonwealth of FLORIDA )  
County of PALM BEACH )

On July 24, 2014 before me, Gary Pettit (Name/Title of Notary) personally appeared Ryan Baker (Name of Signer) who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that s/he executed the same in his/her authorized capacity, and that by his/her signature on the instrument the person, or entity upon behalf of which the person acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State/Commonwealth of Florida that the foregoing paragraph is true and correct. WITNESS my hand and official seal.

Signature: \_\_\_\_\_



RECEIVED AND AGREED TO BY ASSIGNEE LOCL Pharma, Inc.


Date: 7/24/14 Paul Bosse, President

State/Commonwealth of FLORIDA )  
County of PALM BEACH )

On July 24, 2014 before me, Gary Pettit (Name/Title of Notary) personally appeared Paul Bosse (Name of Signer) who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that s/he executed the same in his/her authorized capacity, and that by his/her signature on the instrument the person, or entity upon behalf of which the person acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State/Commonwealth of Florida that the foregoing paragraph is true and correct. WITNESS my hand and official seal.

Signature: \_\_\_\_\_



**Annex A**

Application No.	Patent No.	Filing Date	Issue Date	Title
2,665,841	N/A	10/9/2007	N/A	PHARMACEUTICAL COMPOSITIONS
07871139.7	N/A	10/9/2007	N/A	PHARMACEUTICAL COMPOSITIONS
14177981.9	N/A	10/9/2007	N/A	PHARMACEUTICAL COMPOSITIONS
10105451.9	N/A	10/9/2007	N/A	PHARMACEUTICAL COMPOSITIONS
2009-531645	N/A	10/9/2007	N/A	PHARMACEUTICAL COMPOSITIONS
2013-242699	N/A	10/9/2007	N/A	PHARMACEUTICAL COMPOSITIONS
US2007/80831	N/A	10/9/2007	N/A	PHARMACEUTICAL COMPOSITIONS
60/948,375	N/A	7/6/2007	N/A	PHARMACEUTICAL COMPOSITIONS
60/850,451	N/A	10/9/2006	N/A	PHARMACEUTICAL COMPOSITIONS
60/921,563	N/A	4/3/2007	N/A	PHARMACEUTICAL COMPOSITIONS
14/099,432	N/A	12/6/2013	N/A	PHARMACEUTICAL COMPOSITIONS
12/444,521	8,653,066	2/4/2010	2/18/2014	PHARMACEUTICAL COMPOSITIONS
2,749,273	N/A	1/9/2009	N/A	PHARMACEUTICAL COMPOSITIONS
09700524.3	N/A	1/9/2009	N/A	PHARMACEUTICAL COMPOSITIONS
2010-542386	N/A	1/9/2009	N/A	PHARMACEUTICAL COMPOSITIONS
2013-237727	N/A	1/9/2009	N/A	PHARMACEUTICAL COMPOSITIONS
US2009/30662	N/A	1/9/2009	N/A	PHARMACEUTICAL COMPOSITIONS
61/020,139	N/A	1/9/2008	N/A	PHARMACEUTICAL COMPOSITIONS
12/351,704	8,124,126	1/9/2009	2/28/2012	PHARMACEUTICAL COMPOSITIONS
13/347,552	N/A	1/10/2012	N/A	PHARMACEUTICAL COMPOSITIONS
14/036,946	N/A	9/25/2013	N/A	PHARMACEUTICAL COMPOSITIONS
61/043,037	N/A	4/7/2008	N/A	PHARMACEUTICAL COMPOSITIONS
61/060,758	N/A	6/11/2008	N/A	PHARMACEUTICAL COMPOSITIONS
61/166,511	N/A	4/3/2009	N/A	PPROMETHAZINE OR PROMETHAZINE SALT COMPOSITIONS
61/321,199	N/A	4/6/2010	N/A	PPROMETHAZINE OR PROMETHAZINE SALT COMPOSITIONS
2,767,576	N/A	7/8/2010	N/A	PHARMACEUTICAL COMPOSITIONS
10797879.3	N/A	7/8/2010	N/A	PHARMACEUTICAL COMPOSITIONS
12111143.9	N/A	7/8/2010	N/A	PHARMACEUTICAL COMPOSITIONS
US2010/41433	N/A	7/8/2010	N/A	PHARMACEUTICAL COMPOSITIONS
61/223,999	N/A	7/8/2009	N/A	PHARMACEUTICAL COMPOSITIONS
61/224,424	N/A	7/9/2009	N/A	PHARMACEUTICAL COMPOSITIONS
14/244,455	N/A	4/3/2014	N/A	PHARMACEUTICAL COMPOSITIONS
12/967,423	8,728,522	12/14/2010	5/20/2014	PHARMACEUTICAL COMPOSITIONS
61/750,976	N/A	1/10/2013	N/A	PHARMACEUTICAL COMPOSITIONS
61/926,777	N/A	1/13/2014	N/A	PHARMACEUTICAL COMPOSITIONS
61/916,539	N/A	12/16/2013	N/A	PHARMACEUTICAL COMPOSITIONS
61/915,723	N/A	12/13/2013	N/A	PHARMACEUTICAL COMPOSITIONS
61/977,845	N/A	4/10/2014	N/A	PHARMACEUTICAL COMPOSITIONS
62/020,597	N/A	7/3/2014	N/A	PHARMACEUTICAL COMPOSITIONS
61/926,779	N/A	1/13/2014	N/A	PHARMACEUTICAL COMPOSITIONS